COMMUNIQUÉS West-GlobeNewswire

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
03/03/2026
Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung function AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a [...]
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
03/03/2026
NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through [...]
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
03/03/2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
03/03/2026
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money. RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a [...]
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
03/03/2026
Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needs CAMBRIDGE, Mass [...]
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
03/03/2026
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests [...]
Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
03/03/2026
- CEO Danny Yeung makes personal investment in this round of approximately $750,000, up from investment of approximately $502,000 in November 2025 NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited ( [...]
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
03/03/2026
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs [...]
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
03/03/2026
Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader [...]
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
03/03/2026
CNP-104 improved key cholestasis endpoints at one year, including a composite serum alkaline phosphatase (ALP) and bilirubin biochemical response Durable effects observed across liver stiffness, prognostic risk markers [...]
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
03/03/2026
Echocardiography outcomes show treated patients having reduced negative remodeling of heart volumes SUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell- [...]
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
03/03/2026
Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health Sufficient clinical samples collected to support statistical analysis and FDA submission Company [...]
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
03/03/2026
-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to [...]
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
03/03/2026
Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis ARQ-234 is a potent fusion-protein agonist of [...]
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
03/03/2026
RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
NDT Pharmaceuticals Highlights Enhanced Omni-Channel Positioning; Sets Stage for 2026 Growth with Strategic Marketing Expansion
03/03/2026
ATHENS, Ga., March 03, 2026 (GLOBE NEWSWIRE) -- NDT Pharmaceuticals, Inc. (OTC: NDTP) (“Company”), a pioneer in eco-friendly biosafety and health solutions, announces a significant strengthening of its e-commerce [...]
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
03/03/2026
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
03/03/2026
GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings [...]
Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)
03/03/2026
Approval expands indication of JUXTAPID ® to include children 2 years of age and older with HoFH This announcement was made during the week of Rare Disease Day, which aims to raise awareness about the impact of rare [...]

Pages